Protein levels could predict if bowel cancer patients will benefit from Avastin

October 23, 2012

Comparing levels of specific proteins that the drug Avastin targets could identify patients with advanced bowel cancer who will benefit from the treatment, according to research published in Clinical Cancer Research.

, or , has been shown to increase survival from bowel cancer in around ten to 15 per cent of patients, but it has been impossible to predict who will benefit.

Avastin works by targeting and blocking the VEGF-A , two major forms of which are VEGF165 and VEGF165b.

VEGF165 helps cancers to grow new , so they can get food and oxygen from the blood - all cancers need a blood supply to be able to survive and grow. Its sister protein, VEGF165b, has the opposite effect and acts as a brake on this growth.

Cancer Research UK funded scientists at the University of Bristol looked at the effect Avastin had on patients with different levels of VEGF165b and compared this with patients who were not given the drug at all.

Those with low levels of VEGF165b survived three months longer without the disease progressing compared to patients not treated with Avastin. But patients with higher levels of the protein saw no benefit from Avastin and survived no longer than as those who were not given the drug.

Avastin blocks both forms of VEGF-A, so in patients with lower levels of VEGF165b more Avastin may be available to block the blood vessel promoting protein VEGF165, eventually starving the cancer.

Professor David Bates, lead researcher from the University of Bristol's School of Physiology and , said: "Avastin has shown great potential for a minority of people with bowel cancer, but it's been impossible to predict who will benefit from the drug. Currently, Avastin is not approved by NICE for patients with advanced bowel cancer because they feel that the benefit to an unknown minority of patients does not justify the cost of treatment.

"We now need to look at cancer samples from a larger group of patients about to start taking Avastin and determine if the amount of VEGF165b can accurately identify those patients that will benefit and so potentially open a new treatment option for some people with advanced bowel cancer."

is the third most common cancer in the UK with around 41,000 people diagnosed each year. Survival rates have doubled over the last 40 years but 16,000 people still die from the disease.

Dr Julie Sharp, senior science information manager at Cancer Research UK, said: "New targeted treatments can be hugely beneficial for certain patients, depending on the characteristics of their tumour. But, we don't always know who these patients are. This work takes researchers a step closer to developing a suitable test so doctors can give Avastin to those people it will really make a difference to."

Explore further: Avastin no benefit to older lung cancer patients: study

Related Stories

Avastin no benefit to older lung cancer patients: study

April 17, 2012
(HealthDay) -- Medicare patients who have advanced non-small cell lung cancer appear to get no survival benefit from adding the drug Avastin to standard chemotherapy, researchers from the Dana-Farber Cancer Institute report.

Blood proteins may identify vulnerability of pancreatic cancers to avastin

June 7, 2011
(Medical Xpress) -- Tiny tumor proteins circulating in blood may be used to identify which pancreatic cancer patients would benefit from the drug Avastin, researchers at Duke University Medical Center have found.

US revokes Roche's Avastin for breast cancer

November 18, 2011
US health officials on Friday revoked the authorization of Roche's Avastin for breast cancer treatment, saying it concluded the drug had "not been shown to be safe and effective for that use."

Avastin disappoints against ovarian cancer

December 28, 2011
Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer, too. Two studies found it did not improve survival for most of these patients and kept their ...

Recommended for you

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

A metabolic treatment for pancreatic cancer?

August 15, 2017
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research ...

Skewing the aim of targeted cancer therapies

August 15, 2017
Headlines, of late, have touted the successes of targeted gene-based cancer therapies, such as immunotherapies, but, unfortunately, also their failures.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.